Expert Interview
An overview of the hereditary angioedema (HAE) treatment landscape with a focus on new therapies in development by Kalvista, Astria, and Pharvaris
Ticker(s): PHVS, KALV, ATXSInstitution: Children's Hospital Colorado
- Assistant Professor at the University of Colorado School of Medicine and Fellowship Director of Allergy and Immunology.
- Treats 12 patients with HAE, over 50 patients with spontaneous urticaria and 150 total patients with EoE.
- Clinical interests include food allergy, eosinophilic esophagitis, asthma, allergic rhinitis, eczema, drug allergy and urticaria.
A hematologist with experience in treating hereditary angioedema.
Added By: slingshot_insightsCould you please you explain the mechanism of action of PHVS416 and how it differs from other treatments for hereditary angioedema?
What are the primary endpoints of the ongoing clinical trials for PHVS416?
How do the early-stage clinical trial results of PHVS416 compare to other drugs currently available for hereditary angioedema?
How does PHVS416 fit into the current treatment landscape for hereditary angioedema?
Can you discuss any potential advantages of PHVS416 over current treatments for hereditary angioedema?
What do you think are the biggest challenges facing PHVS416 as it moves through clinical trials?
What is your overall impression of PHVS416 and its potential to be a successful treatment for hereditary angioedema?
Added By: slingshot_insightsWhat do you think are the biggest potential barriers to adoption of PHVS416 in the market?
Can you discuss any potential side effects of PHVS416 and how they compare to side effects of current treatments for hereditary angioedema?
What are your thoughts on the potential pricing and reimbursement of PHVS416 in the market?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
